CytoMed Therapeutics Limited Diluted Earnings Loss Per Share
CytoMed Therapeutics Limited (GDTC) reported Diluted Earnings Loss Per Share of -0.34 SGD/shares for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Income Statement › Earnings Per Share
ifrs-full:DilutedEarningsLossPerShare · last filed 2026-03-31
SGD/shares
| Period end | Diluted Earnings Loss Per Share 12 month |
|---|---|
| 2025-12-31 | -0.34 SGD/shares 20-F · filed 2026-03-31 |
| 2024-12-31 | -0.22 SGD/shares 20-F · filed 2026-03-31 |
| 2023-12-31 | -0.39 SGD/shares 20-F · filed 2026-03-31 |
| 2022-12-31 | -0.40 SGD/shares 20-F · filed 2025-04-28 |
| 2021-12-31 | -0.30 SGD/shares 20-F · filed 2024-04-22 |
| 2020-12-31 | -0.33 SGD/shares 20-F · filed 2023-05-01 |
USD/shares
| Period end | Diluted Earnings Loss Per Share 12 month |
|---|---|
| 2025-12-31 | -$0.27 20-F · filed 2026-03-31 |
| 2024-12-31 | -$0.16 20-F · filed 2025-04-28 |
| 2023-12-31 | -$0.29 20-F · filed 2024-04-22 |
| 2022-12-31 | -$0.30 20-F · filed 2023-05-01 |